AlphaCentric Advisors LLC Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

AlphaCentric Advisors LLC acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,478 shares of the company’s stock, valued at approximately $287,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 167.8% in the 1st quarter. Acadian Asset Management LLC now owns 164,568 shares of the company’s stock valued at $3,240,000 after purchasing an additional 103,120 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at about $1,450,000. Dimensional Fund Advisors LP increased its stake in shares of Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Kiniksa Pharmaceuticals by 8.1% in the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after purchasing an additional 1,435 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 159.8% in the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,692 shares of company stock worth $2,950,315. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 4.4 %

NASDAQ:KNSA opened at $21.48 on Tuesday. The stock has a fifty day moving average price of $25.40 and a 200 day moving average price of $22.53. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $14.12 and a 12-month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the prior year, the business earned ($0.20) earnings per share. The firm’s quarterly revenue was up 67.4% on a year-over-year basis. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.47 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Evercore ISI boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Wedbush boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $34.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.